We have previously confirmed that a synthesized FXR antagonist, compound‐T3, reduced plasma non‐HDL‐cholesterol levels and also elevated HDL‐cholesterol levels in a primate model.21, 22 However, the development of a rodent model with similar disease conditions to human hyperlipidemia would be still useful for the further comprehension of this new type of agent. The gene discussed is NR1H4; the disease is hyperlipidemia.